New study offers hope to people with lung cancer
Dr. Steven Garner weighs in
- Duration 3:26
- Date Sep 10, 2012
Dr. Steven Garner weighs in
Also in this playlist...
This transcript is automatically generated
And the doctor is in now a brand new study offers hope for people with a deadly form of lung cancer.
Researchers say squamous cell lung cancer may be treatable with new drugs that are already in the pipeline or.
Could be easily developed that is big news since this particular kind of cancer.
Kills approximately 400000.
People worldwide it.
Talk about what doctor Steven garner he's the chairman of radiology at New York Methodist Hospital.
So what they've done is is they've taken a look at the genetic mutation that causes cancer.
And they found sort of a weakness in the mutation.
Well why this cancer carpets and have to go back -- -- cancers when the cells thought growing out of control.
-- why should we start going out of control it seems it's due to a mutation or change in the normal genes that the person is inherited so you inherited certain genes were you born.
Maybe you smoke in the Kwazulu mutation of the gene that and records the cells for -- rising star of the mets' lead to cancer.
So the doctors are saying that this me sort of -- the era where we don't talk about lung cancer anymore warm -- you know and liver cancer something like that.
Go after the individual cancer no matter where it lives because the wrong way to think of it now in terms of a breast or kidney or -- long.
It's his group of core set of mutations it's not just -- it's usually several maybe ten mutations that you have.
And you finding similarities of course different chances so instead of using the barbaric chemotherapy that we use them make people sick their hair falls out we too good and and and -- cells.
Now we just target the cancer cells and you don't have all those problems right because chemotherapy is a poison your putting poison in your body hoping to kill more of the cancer cells.
Exactly this is going to be a very different kind of thing it's targeting specifically.
The mutated cancer cells to a commutation does is it's.
Number one it tells of the fools the body says no longer think of these cancer cells is bears -- -- body starts stops making your response to it.
So that's one thing it does the other thing it does -- turn the on switch on to -- -- big Mormon and more cells.
So you have those two things going on -- the body's not recognizing that it's a tumor.
And also the good genes -- telling the tumor to grow a lot.
But if we could devise some medication that would turn off the turn the switch back off and and -- a body -- a bad -- you better go after it.
And you could cure you say if we could devise but it it's my understanding some of these drugs are short of already in the pipeline more than 60% of the patient's drug mutation have drugs out there that would be good for them.
And in the whole thing that allowed this to happen was a different way in the -- where we look at the genome human genome there's 21000 genes -- -- to look at them one at a time.
-- get a snapshot of -- with the -- And it's it's very quick so you could -- some more cancer and get a quick idea of where the nutritionists -- and no more I mean if this thing holds true.
The potential of no more chemotherapy and and the sickness and all that.
That would be just an amazing boost for so many can one -- -- -- it's going to be done instead of starting like from lung cancer one hospital and in the during this trial.
We can have -- -- by their private doctor and and go to were made to center in this city.
And in the gonna collaborate with drug company who makes this medication so you're gonna have a different approach to the trial.
Really amazing amazing thing how long till we could see this kind of thing happening.
But three years through when you're gonna have widespread now so -- this is for -- so offensive 25% of oval the long chances.
But theoretically it should be good for all doctor Steven -- that is great news I mean everybody knows somebody who is a cancer victim.